1166 related articles for article (PubMed ID: 23918733)
41. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
42. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
[TBL] [Abstract][Full Text] [Related]
43. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
44. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
45. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by
Vera P; Thureau S; Chaumet-Riffaud P; Modzelewski R; Bohn P; Vermandel M; Hapdey S; Pallardy A; Mahé MA; Lacombe M; Boisselier P; Guillemard S; Olivier P; Beckendorf V; Salem N; Charrier N; Chajon E; Devillers A; Aide N; Danhier S; Denis F; Muratet JP; Martin E; Riedinger AB; Kolesnikov-Gauthier H; Dansin E; Massabeau C; Courbon F; Farcy Jacquet MP; Kotzki PO; Houzard C; Mornex F; Vervueren L; Paumier A; Fernandez P; Salaun M; Dubray B
J Nucl Med; 2017 Jul; 58(7):1045-1053. PubMed ID: 28254869
[TBL] [Abstract][Full Text] [Related]
46. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
[TBL] [Abstract][Full Text] [Related]
47. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071
[TBL] [Abstract][Full Text] [Related]
48. Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements.
Hatt M; Cheze-Le Rest C; Aboagye EO; Kenny LM; Rosso L; Turkheimer FE; Albarghach NM; Metges JP; Pradier O; Visvikis D
J Nucl Med; 2010 Sep; 51(9):1368-76. PubMed ID: 20720054
[TBL] [Abstract][Full Text] [Related]
49. Defining a radiotherapy target with positron emission tomography.
Black QC; Grills IS; Kestin LL; Wong CY; Wong JW; Martinez AA; Yan D
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1272-82. PubMed ID: 15519800
[TBL] [Abstract][Full Text] [Related]
50. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
51. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
[TBL] [Abstract][Full Text] [Related]
52. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
[TBL] [Abstract][Full Text] [Related]
53. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Kimura N; Ishikawa S; Okuda M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):236-45. PubMed ID: 17909790
[TBL] [Abstract][Full Text] [Related]
54. Variation in background intensity affects PET-based gross tumor volume delineation in non-small-cell lung cancer: the need for individualized information.
Chen GH; Yao ZF; Fan XW; Zhang YJ; Gao HQ; Qian W; Wu KL; Jiang GL
Radiother Oncol; 2013 Oct; 109(1):71-6. PubMed ID: 24060171
[TBL] [Abstract][Full Text] [Related]
55. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
[TBL] [Abstract][Full Text] [Related]
56. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer.
Huang T; Civelek AC; Li J; Jiang H; Ng CK; Postel GC; Shen B; Li XF
J Nucl Med; 2012 Aug; 53(8):1262-8. PubMed ID: 22717978
[TBL] [Abstract][Full Text] [Related]
57. Comparison of primary tumour volumes delineated on four-dimensional computed tomography maximum intensity projection and (18) F-fluorodeoxyglucose positron emission tomography computed tomography images of non-small cell lung cancer.
Duan Y; Li J; Zhang Y; Wang W; Sun X; Fan T; Shao Q; Xu M; Guo Y; Shang D
J Med Imaging Radiat Oncol; 2015 Oct; 59(5):623-30. PubMed ID: 25754243
[TBL] [Abstract][Full Text] [Related]
58. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
[TBL] [Abstract][Full Text] [Related]
59. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
[TBL] [Abstract][Full Text] [Related]
60. Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Scheffler M; Zander T; Nogova L; Kobe C; Kahraman D; Dietlein M; Papachristou I; Heukamp L; Büttner R; Boellaard R; Lammertsma AA; Querings S; Stoelben E; Engel-Riedel W; Neumaier B; Wolf J
PLoS One; 2013; 8(1):e53081. PubMed ID: 23308140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
